Key Points
- Insider buying: Ije Nwokori acquired 232 shares of Dr. Martens on April 14 at an average price of GBX 65, having also bought 219 shares on February 11 at GBX 69.
- Analyst stance: Two analysts rate the stock a Buy and two rate it Hold, giving a MarketBeat average rating of "Moderate Buy" and a reported consensus price target of GBX 6,000.
- Market snapshot: LON:DOCS opened at GBX 66.40 with a market cap of £641.91 million, a one‑year range of GBX 49.53–100.87, and a 50‑day/200‑day moving average of GBX 65.50/75.75 respectively.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori acquired 232 shares of Dr. Martens stock in a transaction dated Tuesday, April 14th. The stock was bought at an average price of GBX 65 per share, with a total value of £150.80.
Ije Nwokori also recently made the following trade(s):
- On Wednesday, February 11th, Ije Nwokori acquired 219 shares of Dr. Martens stock. The stock was bought at an average price of GBX 69 per share, with a total value of £151.11.
Dr. Martens Trading Up 0.9%
LON:DOCS opened at GBX 66.40 on Thursday. The company has a debt-to-equity ratio of 120.66, a current ratio of 2.18 and a quick ratio of 1.13. The firm has a market capitalization of £641.91 million, a price-to-earnings ratio of 39.06, a price-to-earnings-growth ratio of 6.40 and a beta of 0.24. Dr. Martens plc has a one year low of GBX 49.53 and a one year high of GBX 100.87. The business has a fifty day moving average price of GBX 65.50 and a 200-day moving average price of GBX 75.75.
Analysts Set New Price Targets
Several research analysts recently weighed in on DOCS shares. Berenberg Bank reaffirmed a "buy" rating on shares of Dr. Martens in a report on Tuesday, January 27th. Royal Bank Of Canada reaffirmed a "sector perform" rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of GBX 6,000.
Get Our Latest Stock Analysis on Dr. Martens
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
